Advertisement
Editorial: The unaffordable cost of M&A-driven drug prices

Editorial: The unaffordable cost of M&A-driven drug prices

By Merrill Goozner  |  August 27, 2016

There still is no connection between the price of new drugs and the cost of discovering and developing them, even though the pharmaceutical industry has argued for years that such a link was the primary justification for high prices.

FDA approves first pill to treat all forms of hepatitis C

By Associated Press  |  June 28, 2016

Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.

Gilead paying up to $1.2B for Nimbus unit, drug, technology

By Associated Press  |  April 04, 2016

Biologic drugmaker Gilead Sciences is buying a subsidiary of Nimbus Therapeutics and its experimental medicine for an increasingly prevalent metabolic disorder that causes dangerous fat buildup in the liver.

Editorial: Keep CMS' value-based pay off my Medicare drugs!

Editorial: Keep CMS' value-based pay off my Medicare drugs!

By Merrill Goozner  |  March 12, 2016

Everyone is in favor of value-based reimbursement in healthcare, right? If you're still wearing those rose-colored glasses, take a closer look at last week's reaction to Medicare's proposal to test new ways of paying for drugs administered in physician offices and hospital outpatient departments.

Could Massachusetts have the tool to fix high drug costs?

Could Massachusetts have the tool to fix high drug costs?

By Lisa Schencker  |  February 03, 2016

There might be another tool in the battle against high drug costs: state consumer protection laws. A potential lawsuit in Massachusetts against drugmaker Gilead over its costly hepatitis C drugs could, if successful, forge a new path for states working to combat the high costs of certain drugs.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print